Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
12:00am, Monday, 10'th Aug 2020
Today, Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the
Analysts Offer Predictions for Minerva Neurosciences Inc’s Q3 2020 Earnings (NASDAQ:NERV)
11:34pm, Sunday, 09'th Aug 2020
Minerva Neurosciences Inc (NASDAQ:NERV) – Research analysts at William Blair lifted their Q3 2020 earnings per share (EPS) estimates for Minerva Neurosciences in a report released on Monday, August
How Much Did Minerva Neurosciences'(NASDAQ:NERV) Shareholders Earn From Share Price Movements Over The Last Three Years?
01:30pm, Wednesday, 05'th Aug 2020
Many investors define successful investing as beating the market average over the long term. But in any portfolio...
Axsome Therapeutics: Big Unfolding Catalyst (NASDAQ:AXSM)
09:19am, Wednesday, 05'th Aug 2020
Axsome continues to deliver a flurry of positive catalysts for various pipeline molecules. Despite subpar data for the treatment-resistant depression, AXS-05 generated extremely robust results for oth
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
10:10am, Tuesday, 04'th Aug 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lumos Pharma
Minerva Neurosciences (NERV) Q2 2020 Earnings Call Transcript
11:01pm, Monday, 03'rd Aug 2020
Image source: The Motley Fool. Minerva Neurosciences (NASDAQ: NERV)Q2 2020 Earnings CallAug 03, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remar
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
11:30am, Monday, 03'rd Aug 2020
WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou
Usona Institute Publishes Breakthrough Development in Scalable Psilocybin Synthesis
12:00am, Monday, 03'rd Aug 2020
Usona Institute has published a breakthrough technique in kilogram-scale synthesis of pharmaceutical grade psilocybin in an open-access journal.
Reviewing Wize Pharma (OTCMKTS:WIZP) and Minerva Neurosciences (OTCMKTS:NERV)
02:20am, Sunday, 02'nd Aug 2020
Wize Pharma (OTCMKTS:WIZP) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
12:00pm, Monday, 27'th Jul 2020
Management to host conference callWALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of
Early life stress is associated with youth-onset depression for some types of stress but not others
11:18pm, Saturday, 25'th Jul 2020
A study in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), published by Elsevier, reports that individuals exposed to early life stress (ELS) were more likely to de�
People with depression have stronger emotional responses to negative memories
11:16pm, Saturday, 25'th Jul 2020
A study investigates the brain mechanisms underlying autobiographical memory disturbance in depression People with major depressive disorder (MDD) feel more negative emotion when remembering painfu…
